A randomized comparative study of safety and efficacy of immediate release glucosamine HCL and glucosamine HCL sustained release formulation in the treatment of knee osteoarthritis: A proof of concept study

Kulkarni, Chanda; Leena, A; K, Lohit; Mishra, Devesh; Saji, M J

doi:10.4103/0976-500x.92515

Cited by 3 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical trials, consumption of either glucosamine or chondroitin sulfate (CS) has been associated with a reduction in joint pain, improvement of joint function and reduction of joint space narrowing in patients with OA. 9 - 22 However, there is conflicting evidence as to the effectiveness of such treatments. 23 - 30 In vitro studies using glucosamine alone have found positive effects such as decreased interleukin-1 (IL-1) induced expression of matrix metalloproteinases, MMP-3 and MMP-13, cyclooxygenase-2 (COX-2), and nitric oxide synthase, reduced aggrecan degradation, and increased synthesis of aggrecan core protein 31 - 36 while others have found a decrease in prostaglandin E 2 (PGE 2 ) production induced by IL-1.…”

Section: Introductionmentioning

confidence: 99%

Glucosamine Hydrochloride but Not Chondroitin Sulfate Prevents Cartilage Degradation and Inflammation Induced by Interleukin-1α in Bovine Cartilage Explants

et al. 2015

View full text Add to dashboard Cite

ObjectiveGlucosamine hydrochloride (GH) and chondroitin sulfate (CS) are commonly used for the treatment of osteoarthritis (OA). The aim of this study was to assess their effects, alone and in combination, on preventing aggrecan degradation and inflammation in an in vitro model of OA.DesignTo test the effects of GH and/or CS as a preventative treatment, cartilage explants were pretreated with the compound(s) using concentrations that showed no detrimental effect on chondrocyte viability. Interleukin-1α (IL-1α) was added to induce cartilage degradation, supernatant and explants were analyzed for proteoglycan degradation products, aggrecanase mRNA expression and activity, and for the release of inflammatory markers.ResultsFollowing treatment with IL-1α, 2 mg/mL dose of GH pretreatment was associated with a reduction of glycosaminoglycan release, reduced generation of the pathological interglobular domain aggrecan catabolites, decreased mRNA levels of ADAMTS-4 and -5 and reduced activity of ADAMTS-4. In contrast, CS alone did not have a significant effect on IL-1α-induced cartilage degradation and the addition of 0.4 mg/mL CS to 2 mg/mL GH did not further inhibit IL-1α-induced activity. Pretreatment with 2 mg/mL GH also reduced the release of inflammatory markers, prostaglandin E2 and nitric oxide induced by IL-1α while CS did not have a significant effect.ConclusionsThe results suggest that GH prevents cartilage degradation mediated by aggrecanases ADAMTS-4 and -5, and may also reduce inflammation. This could be part of the mechanisms by which GH is effective in maintaining joint integrity and function, and preventing or delaying early symptoms of OA.

show abstract

Section: Introductionmentioning

confidence: 99%

Glucosamine Hydrochloride but Not Chondroitin Sulfate Prevents Cartilage Degradation and Inflammation Induced by Interleukin-1α in Bovine Cartilage Explants

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In addition, Nakamura et al showed that glucosamine significantly improved pain and swelling of arthritic joints compared with placebo in patients with rheumatoid arthritis (RA) . Matsuno et al , however, concluded that glucosamine was more effective for OA than RA , and Kulkarni et al reported that glucosamine HCl improved pain in 59 patients with knee OA . Recently, a randomized, double‐blind, placebo‐controlled trial by Sterzi et al showed that glucosamine HCl combined with chondroitin sulfate and bio‐curcumin was effective for knee OA .…”

Section: Introductionmentioning

confidence: 99%

Protective effect of boiogito extract with glucosamine HCl against adjuvant‐induced arthritis in rats

Takenaga

Niimi

Hamaguchi

et al. 2018

Traditional & Kampo Medicine

View full text Add to dashboard Cite

Aim: The effect of boiogito extract combined with glucosamine HCl was assessed in adjuvant-induced arthritis (AIA) rats. Methods: Rats received a daily oral mixture of boiogito extract (125 mg/kg) and glucosamine HCl (80 mg/kg) before and after once-off adjuvant injection. Treatment was continued up to the day when blood and/or tissue were collected (day 12 or day 21). Paw swelling, arthritis score, and inflammatory mediators were assessed. Results: Combined treatment was more effective for AIA than either agent alone. Both serum nitric oxide (NO) and tissue NO were significantly suppressed in the adjuvant-uninjected hind paw on day 12. Boiogito extract significantly reduced the tissue level of matrix metalloproteinase (MMP)-13. In addition, interleukin (IL)-1β-induced MMP-13 by SW1353 chondrocytes was dose-dependently suppressed by boiogito extract, while glucosamine HCl had little effect. IL-1β-induced phosphorylation of extracellular signal-related kinase (ERK) was inhibited by the combination of boiogito extract and glucosamine HCl, but was most strongly suppressed by glucosamine HCl alone. Conclusion: Combined treatment with boiogito extract and glucosamine HCl had a protective effect against AIA in rats. This effect was related to strong suppression of MMP-13 production (mainly by boiogito extract) and inhibition of inflammatory mediator production via ERK signaling (mainly by glucosamine HCl).

show abstract

Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial

2012

View full text Add to dashboard Cite

Curcuma longa Linn. is widely used for the treatment of disorders associated with inflammation and was evaluated for its safety and efficacy in the treatment of painful knee osteoarthritis (OA). This was a randomized, single blind, placebo-controlled trial. Total of 120 patients (37 males and 83 females) with primary knee OA received either placebo (400 mg twice daily) or NR-INF-02 (500 mg twice daily) or glucosamine sulphate (GS) (750 mg twice daily) alone or combination of NR-INF-02 and GS for 42 days. The efficacy was assessed during treatment period, on day 21 and day 42. The decrease in severity of pain symptom and function of affected knee as primary efficacy outcome measure was assessed by Visual Analog Scale (VAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale, respectively. The clinical examination of affected joint was measured by an orthopaedic specialist and using a Clinician Global Impression Change (CGIC) scale. The analysis of post-treatment scores following administration of NR-INF-02 using VAS, WOMAC, and CGIC at each clinical visit showed significant decrease (p < 0.05) compared to placebo. NR-INF-02 treated group showed a significant (p < 0.01) decrease in use of rescue medication, along with clinical and subjective improvement compared to placebo. The tolerability and acceptability profile of NR-INF-02 was better during the trial period. The study demonstrates safety and efficacy of NR-INF-02 as a useful treatment option for patients with primary painful knee OA.

show abstract

A randomized comparative study of safety and efficacy of immediate release glucosamine HCL and glucosamine HCL sustained release formulation in the treatment of knee osteoarthritis: A proof of concept study

Cited by 3 publications

References 17 publications

Glucosamine Hydrochloride but Not Chondroitin Sulfate Prevents Cartilage Degradation and Inflammation Induced by Interleukin-1α in Bovine Cartilage Explants

Glucosamine Hydrochloride but Not Chondroitin Sulfate Prevents Cartilage Degradation and Inflammation Induced by Interleukin-1α in Bovine Cartilage Explants

Protective effect of boiogito extract with glucosamine HCl against adjuvant‐induced arthritis in rats

Safety and efficacy of Curcuma longa extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial

Contact Info

Product

Resources

About